Journal of Pharmaceutical Research International

Terminalia catappa Linnaeus (Combretaceae), commonly known as the tropical or Indian almond, is a pantropical coastal tree whose leaves, bark, fruit and seed have long featured in folk medicine across Asia, Africa, the Caribbean and the Pacific. Over the past decade, a substantial body of laboratory and pre-clinical evidence has accumulated around the species, reporting antioxidant, antimicrobial, antidiabetic, hepatoprotective, anti-inflammatory, anticancer, antiparasitic and wound-healing properties, alongside an expanding footprint in aquaculture, food technology and green nanotechnology. This review draws this literature together critically, tracing the principal bioactivities back to their phytochemical basis, which centres on a rich pool of hydrolysable tannins, flavonoids and triterpenoids. The pharmacological findings are weighed alongside toxicological and safety data, which point to a broadly favourable margin at conventional experimental doses but leave important gaps around chronic exposure, reproductive safety and chemical standardisation. Applications in fish and crustacean farming are examined as a maturing translational niche, supported by a growing nutritional and industrial literature on the seed oil and kernel. The ecological behaviour of the species, valued in coastal agroforestry yet naturalised or invasive in some island settings, is also considered. Across the pharmacological domains reviewed, mechanistic clarity, dose standardisation and clinical translation lag well behind the sheer volume of in vitro and rodent data now available. The review concludes that T. catappa is a pharmacologically promising but clinically unproven botanical resource, and that rigorous chemical standardisation, well-designed in vivo and human studies, and transparent reporting of phytochemical variability should now be the field's main priorities if the species is to move from ethnomedical use towards evidence-based application.